WO1998054191A1 - Sels de derive de sulfoxyde optiquement actif - Google Patents
Sels de derive de sulfoxyde optiquement actif Download PDFInfo
- Publication number
- WO1998054191A1 WO1998054191A1 PCT/JP1998/002308 JP9802308W WO9854191A1 WO 1998054191 A1 WO1998054191 A1 WO 1998054191A1 JP 9802308 W JP9802308 W JP 9802308W WO 9854191 A1 WO9854191 A1 WO 9854191A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound according
- preventing
- receptor
- treating
- reference example
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the present invention relates to a novel salt of an optically active sulfoxide derivative, which has an excellent antagonistic effect on substance P and neurokinin A receptors.
- the present inventors have conducted intensive studies over many years on the synthesis of derivatives having tachycun antagonism (especially, substance P antagonism, and antagonism against neurokinin A and B), and as a result of new studies,
- the specific salt of the optically active compound having the absolute configuration of S of spiro [benzo [c] thiophene-1 (3H), 4'-piperidine] -2-2-oxide is compared with the above known compounds. to have a better oral absorption, and found that you have exceptional antagonistic activity against both NK 2 receptors to complete the present invention.
- An object of the present invention is to provide the above-mentioned compound, and another object of the present invention is to provide a medicament comprising the above-mentioned compound as an active ingredient, particularly a prophylactic or therapeutic agent for tachykinin-mediated diseases (prevention or treatment).
- Another object of the present invention is to provide a medicament, in particular, a prophylactic or therapeutic agent (composition for prevention or treatment) of tachykinin-mediated diseases.
- a method for preventing or treating tachykinin-mediated diseases by administering a pharmacologically effective amount thereof to a warm-blooded animal.
- Such prophylactic or therapeutic agents include, for example, ⁇ ⁇ receptor and or N
- K2 receptor inhibitors such diseases include, for example, diseases of the central nervous system, including anxiety, depression, psychiatric disorders and schizophrenia; dementia in AIDS; Neurodegenerative diseases including Alzheimer's disease, Down's syndrome, demyelinating disease, amyotrophic lateral sclerosis, neuropathy, peripheral neuropathy, and neuralgia; chronic obstructive pulmonary disease, bronchitis, pneumonia, bronchoconstriction, Respiratory diseases including asthma, cough; inflammatory bowel disease (IBD), inflammatory diseases including psoriasis, fibrositis, osteoarthritis, osteoarthritis, and rheumatoid arthritis; allergic diseases including eczema; and rhinitis; Hypersensitivity diseases including hypersensitivity diseases to plants; ophthalmologic diseases including conjunctivitis, spring conjunctivitis, spring catarrh, destruction of blood-water-aqueous-water barrier due to various inflammatory eye diseases, increased intraocular pressure, miosis ; Contact
- novel medicine of the present invention comprises a compound selected from the above as an active ingredient
- novel prophylactic or therapeutic agent for tachykinin-mediated diseases of the present invention contains a compound selected from the above as an active ingredient,
- novel ⁇ ⁇ ⁇ receptor and / or NK 2 receptor inhibitor of the present invention contains a compound selected from the above as an active ingredient,
- novel prophylactic or therapeutic agent for asthma and / or bronchitis of the present invention contains a compound selected from the above as an active ingredient,
- the novel agent for preventing or treating rhinitis of the present invention contains a compound selected from the above as an active ingredient
- the novel allergic preventive or therapeutic agent of the present invention comprises a compound selected from the above as an active ingredient
- the novel agent for preventing or treating urinary incontinence of the present invention contains a compound selected from the above as an active ingredient.
- the use of the present invention for producing a medicament comprises using a compound selected from the above,
- the use of the present invention for producing a ⁇ receptor and / or a NK 2 receptor inhibitor comprises using a compound selected from the above,
- the use of the present invention for producing a prophylactic or therapeutic agent for asthma and Z or bronchitis uses a compound selected from the above,
- the use of the present invention for producing a prophylactic or therapeutic agent for rhinitis uses a compound selected from the above,
- the use of the present invention for producing a prophylactic or therapeutic agent for allergy uses a compound selected from the above,
- a compound selected from the above is used.
- the hydrochloride is more preferable.
- the present invention relates to a compound of the present invention, " ⁇ 2-((2R) -1- (3,4-dichlorophenyl) phenyl) -14- (3,4,5-trimethoxybenzinole) -monorefolin-1-2-inole] ] Ethyl ⁇ spiro [benzo (c) thiophene-1 (3H), 4'-piperidine] -1- (2S) -oxide hydrochloride or fumarate ”may be left in the air or In some cases, recrystallization causes absorption of water or a recrystallization solvent to form a solvate, and such salts are also included in the present invention.
- the salt of the optically active sulfoxide derivative of the present invention may be prepared as follows: “111 ⁇ 2-[(2R) 1-1 (3,4-dichlorophenyl) -14-4- (3,4,5-trimethoxybenzoyl) morpholy] -2-yl] ethyl ⁇ Spiro [benzo (c) thiophene-1 (3H), 4'-piperidine] -1- (2S) -oxide is synthesized according to the reference example described later, and is synthesized by a known method. It can be produced by converting into a hydrochloride or a fumarate according to the above.
- the salt of the novel optically active sulfoxide derivative of the present invention has an excellent antagonism to the receptors of substance P and nutcun A, and has low toxicity, so that a preventive or therapeutic agent for tachykinin-mediated diseases,
- diseases of the central nervous system including anxiety, depression, psychiatric disorders and fissures; dementia in AIDS, senile dementia of the Alzheimer type, Alzheimer's disease, Down's syndrome, demyelinating disease, amyotrophic lateral sclerosis, Neurodegenerative diseases including neuropathy, peripheral neuropathy, and neuralgia; chronic obstructive pulmonary disease, bronchitis, pneumonia, bronchoconstriction, asthma, respiratory diseases including cough; inflammatory bowel disease (IBD), psoriasis, binding Inflammatory diseases including histitis, osteoarthritis, degenerative arthritis, and rheumatoid arthritis; allergic diseases including eczema; and rhinitis; hypersensitivity diseases to vines Hyper
- Examples of the dosage form of the salt of the optically active sulfoxide derivative of the present invention include oral administration by tablets, capsules, granules, powders, syrups, etc., and parenteral administration by injections or suppositories. These preparations may include excipients (eg, lactose, sucrose, glucose, mannite, sugar derivatives such as sorbitol; corn starch, potato starch, alpha starch, dextrin, carboxy).
- excipients eg, lactose, sucrose, glucose, mannite, sugar derivatives such as sorbitol; corn starch, potato starch, alpha starch, dextrin, carboxy.
- Starch derivatives such as methyl starch; crystalline cellulose; low-substituted hydroxypropyl cenorellose; Mouth Cellulose derivatives such as sodium; Arabic Rubber; dextran; organic excipients such as pullulan: and silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, magnesium metasilicate aluminate; phosphates such as calcium phosphate; calcium carbonate Carbonates; inorganic excipients such as sulfates such as calcium sulfate; and lubricants (eg, stearic acid, stearin Metal salts of stearic acid, such as calcium phosphate and magnesium stearate; talc; colloidal silica; waxes, such as veegum and gay: boric acid; adipic acid: sulfates, such as sodium sulfate; glycol; Sodium benzoate; DL leucine; sodium salts of fatty acids; sodium lauryl
- Binders for example, polyvinylpyrrolidone, macrogol, and the same compounds as the above-mentioned excipients
- disintegrants for example, the same compounds as the above-mentioned excipients, and Examples include chemically modified starch and celluloses such as croscarmellose sodium, carboxymethyl starch sodium, crosslinked polybutylpyrrolidone, and stabilizers (methyl paraben, propyl paraben).
- the amount used depends on the symptoms, age, administration method and the like.
- the lower limit is 0.01 mg / kg body weight (preferably 0.1 mg / kg body weight) and 100 mg / kg body weight (preferably 50 mg / kg body weight) as the upper limit, and in the case of intravenous administration, 0.0 mg / kg body weight per dose.
- 1 m g / kg body weight (rather preferably is, 0. 0 5 mg / kg body weight), as the upper limit, 1 0 O mg / kg body weight (preferably, 5 0 mg / kg body weight) per day to the It is desirable to administer several times depending on the symptoms.
- the aqueous layer was acidified with concentrated hydrochloric acid under ice-cooling, extracted with ether (500 ml ⁇ 3 times), and the organic layer was dried over anhydrous magnesium sulfate.
- the solvent was distilled off under reduced pressure, the residue was dissolved in methanol (350 ml), concentrated sulfuric acid (10 ml) was added, and the mixture was heated under reflux for 30 minutes. After allowing to cool, neutralized with a saturated aqueous solution of sodium hydrogencarbonate, methanol was distilled off under reduced pressure, and the residue was extracted with methylene chloride (200 ml ⁇ 3 times). After the organic layer was dried over anhydrous magnesium sulfate, the solvent was concentrated under reduced pressure. The residue was distilled under reduced pressure to obtain the desired compound 69.13 g (62%) as a pale yellow oil.
- Lithium aluminum hydride (1.176 g, 0.28 mol) was suspended in 500 ml of anhydrous tetrahydrofuran, and then 3-(3, 4) synthesized in Reference Example 3 (a).
- Methyl phenyl 3-dibutenoate 69.06 g (0.
- the organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was dissolved in chlorophenol 500 ml. Under ice-cooling, 500 ml of 50% trifluoroacetic acid was added dropwise over 30 minutes, and the mixture was further stirred for 30 minutes.
- the reaction solution was diluted with 300 ml of methylene chloride, and the organic layer was washed with water and saturated aqueous sodium hydrogen carbonate, and then dried over anhydrous sodium sulfate.
- the solvent was distilled off under reduced pressure, and the residue was dissolved in 600 ml of acetonitrile, and 35.0 g (329 mmol) of lithium perchlorate and 33.4 g (54%) of 2-aminoethanol were added. (7 mmol) and heated to reflux for 16 hours.
- the reaction solution was cooled to room temperature, diluted with ethyl acetate, washed with a saturated saline solution, and the organic layer was dried over anhydrous sodium sulfate.
- reaction solution was diluted with methylene chloride, washed with 1N hydrochloric acid and saturated saline, and then dried over anhydrous sodium sulfate.
- Dye (Evans blue: 40 mg / kg) was administered into the femoral vein of a guinea pig anesthetized with pentobarbital (30 mg / kg, p.p.), and SP (1 ⁇ g / kg) was immediately administered. Intravenous injection caused an increase in vascular permeability. After 15 minutes, the guinea pig was sacrificed under anesthesia with black-mouthed form, and the amount of dye leaked into the main trachea was measured according to the Harada method (J. Pharm. Pharmacol. 218 (1971)).
- test drug was suspended in a 0.5% tragacanth suspension and orally administered 1 hour before the induction of SP, and its inhibitory effect was determined from the amount of leaked pigment in the test drug-administered group and the non-administered group.
- Table 1 5 0% inhibition dose of (ID 5 0) and 3. 3 mg / kg shows the suppression rate when administered orally. [table 1 ]
- Test Drug ID 50 (mg / kg, po) 3.3 mg / kg Oral Inhibition Rate (%)
- Compound C 44.1 The compounds of the present invention showed activity equivalent to that of the prior art compound C in an in vivo receptor antagonism test.
- Healthy guinea pig (body weight 5 0 0 g longitudinal, hard preparative Les one male guinea pig) with a NK 2 receptor agonist [N le 1 Q] - NKA [4- 1 0] inhibition on airway contraction by The effect was investigated according to a modification of Konzett-Roessler (Naunyn-Schmiedebergs Arch. Exp. Pathol, pharmakol. 195, 71 (1940)) using airway pressure as an index.
- the airway pressure during the artificial respiration is measured by a pressure transducer (Nihon Kohden, TP—200T) attached to the side branch of the tracheal force adjuster, and the sensitivity (Nihon Kohden, AP—601G) ) And recorded on a recorder (Nihon Kohden, WT-685 G).
- the compounds of the present invention exhibited excellent antagonism to both NK i receptor and NK 2 receptor. More specifically, the compounds of the present invention show antagonism to NK receptor which is as strong as that of the prior art, and furthermore, antagonize NK 2 receptor which is superior to that of the prior art. Was.
- a powder is obtained by mixing 5 g of the compound of Example 1, lactose 895 g and 100 g of corn starch in a blender. The powder contains 5 mg of the compound of Example 1 per gram.
- the No. 3 capsule was filled with 180 mg each. A capsule is obtained. The capsule contains 5 mg of the compound of Example 1 per capsule.
- tablets After mixing 5 g of the compound of Example 1, lactose 90 g, corn starch 34 g, crystalline cellulose 20 g and magnesium stearate lg in a blender, tablets are obtained by tableting using a tablet machine. .
- the salt of the novel optically active sulfoxide derivative of the present invention has an excellent antagonism to the receptor for substance P and nuclein kinin A, and has low toxicity, so that it can be used as a preventive or therapeutic agent for tachykinin-mediated diseases. Useful.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cephalosporin Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL336894A PL193115B1 (pl) | 1997-05-30 | 1998-05-27 | Sól (2S)-tlenku 1-{2-[(2R)-(3,4-dichlorofenylo)-4-(3,4,5-trimetoksybenzoilo)morfolin-2-ylo]etylo}spiro[benzo(c)tiofeno-1(3H),4'-piperydyny] |
AT98921817T ATE247122T1 (de) | 1997-05-30 | 1998-05-27 | Salze von optisch aktiven sulfoxid-derivaten |
DE69817178T DE69817178T2 (de) | 1997-05-30 | 1998-05-27 | Salze von optisch aktiven sulfoxid-derivaten |
IL13296298A IL132962A0 (en) | 1997-05-30 | 1998-05-27 | Salts of an optically-active sulfoxide derivative pharmaceutical compositions containing the same and the use thereof |
CA002290392A CA2290392C (en) | 1997-05-30 | 1998-05-27 | Salts of optically active sulfoxide derivative |
EP98921817A EP0987269B1 (en) | 1997-05-30 | 1998-05-27 | Salts of optically active sulfoxide derivative |
AU74515/98A AU732384B2 (en) | 1997-05-30 | 1998-05-27 | Salts of an optically-active sulfoxide derivative |
NZ501332A NZ501332A (en) | 1997-05-30 | 1998-05-27 | Salts of optically active spiro[benzo[c]thiophene-1(3H),4'-piperidin]-2-oxide as antagonists against both P receptors and neurokinin A receptors |
BR9809713-0A BR9809713A (pt) | 1997-05-30 | 1998-05-27 | Composto, medicamento e composição compreendendo o mesmo, uso do composto, e, processos para profilaxia ou tratamento de doenças mediadas com taquicinina, para inibir um receptor nk1 e/ou um receptor nk2, e para profilaxia ou tratamento de asma e/ou bronquite, de rinite, de alergia, e, de incontinência urinária |
DK98921817T DK0987269T3 (da) | 1997-05-30 | 1998-05-27 | Salte af optisk aktivt sulfoxidderivat |
HU0002459A HUP0002459A3 (en) | 1997-05-30 | 1998-05-27 | Salts of optically active sulfoxide derivative, pharmaceutical compositions containing them and use thereof |
IL132962A IL132962A (en) | 1997-05-30 | 1999-11-16 | Sulphoxide oxide salts with optical activity, pharmaceutical preparations containing them and their use |
US09/447,401 US6362179B1 (en) | 1997-05-30 | 1999-11-23 | Salts of an optically-active sulfoxide derivative |
NO995847A NO995847L (no) | 1997-05-30 | 1999-11-29 | Salter av optisk aktivt sulfoksydderivat |
HK00104485A HK1025321A1 (en) | 1997-05-30 | 2000-07-20 | Salts of optically active sulfoxide derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/141805 | 1997-05-30 | ||
JP14180597 | 1997-05-30 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/447,401 Continuation US6362179B1 (en) | 1997-05-30 | 1999-11-23 | Salts of an optically-active sulfoxide derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998054191A1 true WO1998054191A1 (fr) | 1998-12-03 |
Family
ID=15300548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/002308 WO1998054191A1 (fr) | 1997-05-30 | 1998-05-27 | Sels de derive de sulfoxyde optiquement actif |
Country Status (23)
Country | Link |
---|---|
US (1) | US6362179B1 (ja) |
EP (1) | EP0987269B1 (ja) |
KR (1) | KR100432210B1 (ja) |
CN (1) | CN1153773C (ja) |
AT (1) | ATE247122T1 (ja) |
AU (1) | AU732384B2 (ja) |
BR (1) | BR9809713A (ja) |
CA (1) | CA2290392C (ja) |
CZ (1) | CZ296599B6 (ja) |
DE (1) | DE69817178T2 (ja) |
DK (1) | DK0987269T3 (ja) |
ES (1) | ES2202853T3 (ja) |
HK (1) | HK1025321A1 (ja) |
HU (1) | HUP0002459A3 (ja) |
ID (1) | ID23697A (ja) |
IL (2) | IL132962A0 (ja) |
NO (1) | NO995847L (ja) |
NZ (2) | NZ513904A (ja) |
PL (1) | PL193115B1 (ja) |
PT (1) | PT987269E (ja) |
RU (1) | RU2190615C2 (ja) |
TR (1) | TR199902943T2 (ja) |
WO (1) | WO1998054191A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999037642A1 (en) * | 1998-01-23 | 1999-07-29 | Sankyo Company, Limited | Spiropiperidine derivatives |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1352659A4 (en) * | 2000-12-22 | 2004-06-30 | Takeda Chemical Industries Ltd | COMBINATION DRUGS |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028389A1 (fr) * | 1994-04-15 | 1995-10-26 | Yamanouchi Pharmaceutical Co., Ltd. | Compose spiro et composition medicinale issue de ce compose |
WO1996023787A1 (fr) * | 1995-01-30 | 1996-08-08 | Sanofi | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
JPH09235275A (ja) * | 1995-12-01 | 1997-09-09 | Sankyo Co Ltd | 飽和複素環化合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0680607A4 (en) | 1993-01-22 | 1997-06-04 | Adeza Biomedical Corp | ASSAY METHOD FOR IDENTIFYING BREAKAGE OF MEMBRANES IN WOMEN AT RISK OF IMMINENT DELIVERY. |
HU224496B1 (hu) | 1993-05-06 | 2005-10-28 | Merrel Dow Pharmaceuticals Inc. | Pirrolidin-3-il-alkil-piperidin-származékok és e vegyületeket tartalmazó gyógyászati készítmények |
EP0702681A1 (en) | 1993-06-07 | 1996-03-27 | Merck & Co. Inc. | Spiro-substituted azacycles as neurokinin antagonists |
RU2135494C1 (ru) | 1995-12-01 | 1999-08-27 | Санкио Компани Лимитед | Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина |
-
1998
- 1998-05-27 ES ES98921817T patent/ES2202853T3/es not_active Expired - Lifetime
- 1998-05-27 CZ CZ0419599A patent/CZ296599B6/cs not_active IP Right Cessation
- 1998-05-27 TR TR1999/02943T patent/TR199902943T2/xx unknown
- 1998-05-27 BR BR9809713-0A patent/BR9809713A/pt not_active Application Discontinuation
- 1998-05-27 WO PCT/JP1998/002308 patent/WO1998054191A1/ja active IP Right Grant
- 1998-05-27 PT PT98921817T patent/PT987269E/pt unknown
- 1998-05-27 EP EP98921817A patent/EP0987269B1/en not_active Expired - Lifetime
- 1998-05-27 NZ NZ513904A patent/NZ513904A/xx not_active Application Discontinuation
- 1998-05-27 ID IDW991467A patent/ID23697A/id unknown
- 1998-05-27 AT AT98921817T patent/ATE247122T1/de not_active IP Right Cessation
- 1998-05-27 DK DK98921817T patent/DK0987269T3/da active
- 1998-05-27 PL PL336894A patent/PL193115B1/pl not_active IP Right Cessation
- 1998-05-27 RU RU99123631/04A patent/RU2190615C2/ru not_active IP Right Cessation
- 1998-05-27 DE DE69817178T patent/DE69817178T2/de not_active Expired - Lifetime
- 1998-05-27 KR KR10-1999-7010921A patent/KR100432210B1/ko not_active IP Right Cessation
- 1998-05-27 CA CA002290392A patent/CA2290392C/en not_active Expired - Fee Related
- 1998-05-27 IL IL13296298A patent/IL132962A0/xx not_active IP Right Cessation
- 1998-05-27 HU HU0002459A patent/HUP0002459A3/hu unknown
- 1998-05-27 NZ NZ501332A patent/NZ501332A/en unknown
- 1998-05-27 CN CNB988074117A patent/CN1153773C/zh not_active Expired - Fee Related
- 1998-05-27 AU AU74515/98A patent/AU732384B2/en not_active Ceased
-
1999
- 1999-11-16 IL IL132962A patent/IL132962A/en unknown
- 1999-11-23 US US09/447,401 patent/US6362179B1/en not_active Expired - Fee Related
- 1999-11-29 NO NO995847A patent/NO995847L/no not_active Application Discontinuation
-
2000
- 2000-07-20 HK HK00104485A patent/HK1025321A1/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028389A1 (fr) * | 1994-04-15 | 1995-10-26 | Yamanouchi Pharmaceutical Co., Ltd. | Compose spiro et composition medicinale issue de ce compose |
WO1996023787A1 (fr) * | 1995-01-30 | 1996-08-08 | Sanofi | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
JPH09235275A (ja) * | 1995-12-01 | 1997-09-09 | Sankyo Co Ltd | 飽和複素環化合物 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999037642A1 (en) * | 1998-01-23 | 1999-07-29 | Sankyo Company, Limited | Spiropiperidine derivatives |
US6511975B1 (en) | 1998-01-23 | 2003-01-28 | Sankyo Company, Limited | Spiropiperidine derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6096766A (en) | 3-benzylaminopiperidines as tachykinin receptor antagonists | |
US5985896A (en) | Piperidine and morpholine derivatives and their use as therapeutic agents | |
US5830892A (en) | Piperidine and morphonline derivatives and their use as therapeutic agents | |
JP6799596B2 (ja) | ムスカリンm1及び/またはm4受容体のアゴニストとしてのオキシム化合物 | |
US6458830B1 (en) | Tetrahydropyran derivatives and their use as therapeutic agents | |
US5929094A (en) | Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists | |
JP7152430B2 (ja) | 医薬化合物 | |
KR101701533B1 (ko) | 아이속사졸-피리다진 유도체 | |
WO1997019084A1 (en) | Spiro-piperidine derivatives and their use as tachykinin antagonists | |
JP7382406B2 (ja) | ムスカリンm1および/またはm4受容体アゴニストとしてのキノリノンおよびベンゾオキサジン誘導体 | |
US6489343B2 (en) | Tetrahydropyran derivatives and their use as therapeutic agents | |
HRP20030923A2 (en) | Novel piperidinecarboxamide derivatives, method for prreparing same and pharmaceutical compositions containing same | |
WO1998017276A1 (en) | Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists | |
WO1998054191A1 (fr) | Sels de derive de sulfoxyde optiquement actif | |
JPH1143490A (ja) | 光学活性スルホキシド誘導体の塩 | |
US6372754B1 (en) | Spirocyclic ketones and their use as tachykinin antagonists | |
JPH10273489A (ja) | ピロリジン誘導体 | |
KR20060127157A (ko) | 인다놀 유도체 | |
JP2002527423A (ja) | ヒトnk3受容体の選択的アンタゴニストとしてのウレイドピペリジン誘導体 | |
WO1998017660A1 (en) | Phenyl spiroethercycloalkyl tachykinin receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 132962 Country of ref document: IL Ref document number: 98807411.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CZ HU ID IL KR MX NO NZ PL RU TR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2290392 Country of ref document: CA Ref document number: 2290392 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998921817 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09447401 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-4195 Country of ref document: CZ Ref document number: 1019997010921 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 501332 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/011023 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999/02943 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 74515/98 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-4195 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1998921817 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997010921 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 74515/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998921817 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019997010921 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1999-4195 Country of ref document: CZ |